NextPlat (NXPL) EBITDA Margin (2015 - 2026)
NextPlat's (NXPL) quarterly EBITDA Margin came in at 1.07% in Q2 2026, up 1275.0% year-over-year from 0.08% in Q2 2025, and up 90.45% quarter-over-quarter from 11.19% in Q1 2026.
Powered by 
Analysis
NextPlat (NXPL) EBITDA Margin (2015 - 2026) Analysis & Trends
NextPlat (NXPL) has reported EBITDA Margin for 12 consecutive years, with 1.07% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA Margin rose 1275.0% year-over-year to 1.07% in Q2 2026; TTM through Jun 2026 was 14.32%, a 984.0% increase from a year earlier, with the FY2025 full-year figure at 16.57%, up 1828.0% from the prior year.
- EBITDA Margin was 1.07% for Q2 2026 at NextPlat, up from 11.19% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1.07% in Q2 2026 and troughed at 113.46% in Q2 2023.
- A 5-year average of 42.01% and a median of 26.1% in 2022 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin slumped 6006 bps in 2023 and surged 7703 bps in 2024, its largest moves.
- Over 5 years, EBITDA Margin stood at 101.53% in 2022, then grew by 10 bps to 91.12% in 2023, then soared by 85 bps to 14.09% in 2024, then sank by 105 bps to 28.87% in 2025, then soared by 96 bps to 1.07% in 2026.
- The last three EBITDA Margin figures came in at 1.07% (Q2 2026), 11.19% (Q1 2026), and 28.87% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 25.95% |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 15.21% |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -134.08% |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 9.72% |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | -1.07% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.07% |
| Mar 31, 2026 | -11.19% |
| Dec 31, 2025 | -28.87% |
| Sep 30, 2025 | -14.46% |
| Jun 30, 2025 | -13.81% |
| Mar 31, 2025 | -14.96% |
| Dec 31, 2024 | -14.09% |
| Sep 30, 2024 | -52.05% |
| Jun 30, 2024 | -64.14% |
| Mar 31, 2024 | -10.53% |
| Dec 31, 2023 | -91.12% |
| Sep 30, 2023 | -22.74% |
| Jun 30, 2023 | -113.46% |
| Mar 31, 2023 | -43.05% |
| Dec 31, 2022 | -101.53% |
| Sep 30, 2022 | -82.29% |
| Jun 30, 2022 | -53.40% |
| Mar 31, 2022 | -23.33% |
| Dec 31, 2021 | -170.72% |
| Sep 30, 2021 | -99.40% |